WHWK
Whitehawk Therapeutics, Inc.
Healthcare — Biotechnology
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
Buy
2.0 / 5
5 analysts
$3.76
(0.00%)
Target:
$7.20
(91.5%)
Price History
52-Week Range
Sign in to add WHWK to a watchlist or set price alerts.
Fundamentals
| Market Cap | $212.65M |
| P/E Ratio (TTM) | - |
| Forward P/E | -3.69 |
| EPS (TTM) | $-2.49 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -68.54% |
| Debt/Equity | - |
| Recommendation | Buy 2.0 |
| Analyst Target | $7.20 |
| Analysts | 5 |
| Next Earnings | Aug 6, 2026 BMO |
| Indexes | - |
Technical Indicators
| RSI (14) | 57.2 |
| Beta | 0.77 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $5.50 |
| 52-Week Low | $1.57 |
| 50-Day Avg | $4.28 |
| 200-Day Avg | $3.12 |
| Avg Volume | 417.5K |
| Volume | 40.3K |
Performance Analysis
BULLISHWHWK shows predominantly bullish signals based on its fundamentals and technicals.
~
Trading at 56% of its 52-week range.
+
RSI at 57.2 shows positive momentum.
~
Price dropped below the 50-day average but remains above the 200-day — possible short-term weakness.
+
Wall Street consensus is "Buy" from 5 analysts.
+
Average analyst target of $7.20 implies 91.5% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:37 UTC
Back to Screener Export Report